Human papillomavirus: Epidemiology and public health

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 8, 2003, Pages 930-934

  Schiffman, Mark ^a   Castle, Philip E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; VIRUS VACCINE;

ADULT; AGE; CARCINOGENESIS; CHLAMYDIA TRACHOMATIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONDYLOMA; CONFERENCE PAPER; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; DRUG USE; FEMALE; HEALTH EDUCATION; HUMAN; MALE; MULTIPARA; NUTRITIONAL STATUS; PAPANICOLAOU TEST; PERSISTENT VIRUS INFECTION; PRECANCER; PREVALENCE; PUBLIC HEALTH SERVICE; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SMOKING; STANDARD; UTERINE CERVIX CANCER; VIRUS IDENTIFICATION; VIRUS IMMUNITY; VIRUS PARTICLE; WART VIRUS; ARTICLE; DISEASE TRANSMISSION; EDUCATION; HETEROZYGOTE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PATHOGENICITY; PENIS; PUBLIC HEALTH; SKIN; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

CARRIER STATE; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENIS; PRECANCEROUS CONDITIONS; PREVALENCE; PUBLIC HEALTH; RISK FACTORS; SKIN; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0041673351     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518-527.
2. Schiffman M. Epidemiology. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York, NY: Springer-Verlag; 2002:1301-1318.
3. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group: interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
4. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.
5. Castle PE, Shields T, Kirnbauer R, et al. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis. 2002;29:182-187.
6. Andersson-Ellstrom A, Dillner J, Hagmar B, et al. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls: a longitudinal cohort study. Sex Transm Dis. 1996;23:234-238.
7. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3-8.
8. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991; 265:472-477.
9. Marrazzo JM, Koutsky LA, Stine KL, et al. Genital human papillomavirus infection in women who have sex with women. J Infect Dis. 1998;178:1604-1609.
10. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:314-319.
11. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst. 2001;93:843-849.
12. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001;183:8-15.
13. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105-1112.
14. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl. 2000;205:189-193.
15. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1992;84:394-398.
16. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000;87:221-227.
17. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92:464-474.
18. Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers: decreasing prevalence with age despite continuously high sexual activity. Sex Transm Dis. 2000;27:438-445.
19. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235-240.
20. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415-1423.
21. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995; 87:1365-1371.
22. Sherman ME, Schiffman MH, Erozan YS, Wacholder S, Kurman RJ. The Bethesda System: a proposal for reporting abnormal cervical smears based on the reproducibility of cytopathologic diagnoses. Arch Pathol Lab Med. 1992;116: 1155-1158.
23. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
24. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002;360:228-229.
25. Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002;359:1093-1101.
26. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085-1092.
27. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 2001;84:1219-1226.
28. Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis. 2002;185:324-331.
29. Castle PE, Hillier SL, Rabe LK, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev. 2001;10:1021-1027.
30. Giuliano AR. The role of nutrients in the prevention of cervical dysplasia and cancer. Nutrition. 2000;16:570-573.
31. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer. 2000;83:1565-1572.
32. Castle PE, Wacholder S, Sherman ME, et al. A prospective study of high-grade cervical neoplasia among human papillomavirus-infected women. J Natl Cancer Inst. 2002;94:1406-1414.
33. Lowy DR, Schiller JT. Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst Monogr. 1998;23:27-30.
34. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284-292.
35. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.